RhGUS: Phase III data

Top-line data from a double-blind, crossover, U.S. Phase III trial in 12 patients ages 5-35 with MPS VII showed that 4 mg/kg IV UX003 every other week for 24-48 weeks met the primary endpoint of reducing urinary GAG excretion after 24 weeks compared to

Read the full 444 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE